The federal 340B drug discount program provides certain providers with deep discounts on some outpatient drugs. Last year the 340B program saw substantial growth amidst uncertainty related to the use of contract pharmacies. The health care data and analytics firm, IQVIA, reported that in 2021, 340B program sales reached $93.6 billion and grew 15.9% year-on-year. However, last year more pharmaceutical manufacturers announced or implemented a change to not offer the 340B discount to drugs dispensed under contract pharmacy arrangements in certain cases. The growth, policy, and legal issues of the 340B program are significant not only to impacted health care providers and pharmaceutical manufacturers, but also to other stakeholders such as health plans, data vendors, and even Congress.

This virtual symposium hosted by the Business Advancement Center for Health (BACH) in partnership with Leavitt Partners, will review the latest legal and policy questions under discussion in the Courts and Congress and explain how impacted stakeholders are responding to the ever-evolving 340B program landscape.